Clinical Trial Results:
Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.
Summary
|
|
EudraCT number |
2016-002413-22 |
Trial protocol |
IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Aug 2022
|
First version publication date |
25 Aug 2022
|
Other versions |
|
Summary report(s) |
Research Letter_Final_paper_BeOne |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.